AM

Amrita Mishra

Active Director Director DIN 08989640
DIN 08989640 First appointment Oct 2020 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2020
Shareholding value •••• Premium profile

About Amrita Mishra

Data last updated:

Amrita Mishra is a Director at Olampus Pharmaceuticals Private Limited (since 2020). The company operates in Healthcare. Olampus Pharmaceuticals Private Limited reported revenue of ₹49.4 Lakh (FY 2024).

DIN 08989640
Primary Designation Director
Industry Healthcare
First Appointment 14 Oct 2020
Oldest Company Age 16 yrs
Largest company Olampus Pharmaceuticals Private Limited · ₹49.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Oct 20202010₹49.4 Lakh (FY 2024)Active

Board colleagues of Amrita Mishra

Directorship timeline

Open interactive timeline →
Olampus Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Amrita Mishra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amrita Mishra

Amrita Mishra currently holds 1 directorship: Olampus Pharmaceuticals Private Limited (Director, since 14 Oct 2020, revenue ₹49.4 Lakh (FY 2024)).

Amrita Mishra was first appointed on 14 Oct 2020 as Director at Olampus Pharmaceuticals Private Limited.

The current boards of Amrita Mishra's companies include Nitesh Mishra (Olampus Pharmaceuticals Private Limited), Rajeev Ranjan (Olampus Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available